Showing 2,841 - 2,860 results of 3,081 for search '"Stem cell', query time: 0.09s Refine Results
  1. 2841

    Exploring the Active Constituents of <i>Andrographis paniculata</i> in Protecting the Skin Barrier and the Synergistic Effects with Collagen XVII by Heng Xu, Shiying Lan, Simin Lin, Anjing Wang, Yuanlin Luo, Jing Wang, Zhenzhong Yang

    Published 2025-01-01
    “…Furthermore, the protective effects of AHE and its active ingredients on UVB-damaged epidermal stem cells were investigated. Notably, the combined treatment with andrographolide and collagen XVII enhanced the viability of UVB-damaged epidermal stem cells, increased the expression of stemness markers integrin β1 and p63, and decreased the expression of the differentiation marker keratin 10. …”
    Get full text
    Article
  2. 2842

    Genome-wide transcriptome analysis and drug target discovery reveal key genes and pathways in thyroid cancer metastasis by Minjing Zou, Amal Qattan, Monther Al-Alwan, Hazem Ghebeh, Naif Binjumah, Latifa Al-Haj, Khalid S. A. Khabar, Abdulmohsen Altaweel, Falah Almohanna, Abdullah M. Assiri, Abdelilah Aboussekhra, Ali S. Alzahrani, Ali S. Alzahrani, Yufei Shi

    Published 2025-02-01
    “…Mertk, a member of the TAM (Tyro, Axl, Mertk) family of RTKs, was also overexpressed in Met cells, which led to increased MAPK activation, epithelial–mesenchymal transition (EMT), and enrichment of cancer stem cells. …”
    Get full text
    Article
  3. 2843
  4. 2844
  5. 2845

    Chronic Myeloid Leukemia: Part II—Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective by Ehab L. Atallah, Rodrigo Maegawa, Dominick Latremouille-Viau, Carmine Rossi, Annie Guérin

    Published 2022-08-01
    “…Three-month inpatient IRs were 0.6, 0.7, and 1.4 days in the CML-CP On Treatment, CML-CP Post-Discontinuation, and CML-AP/BC cohort, respectively, with mean costs of $5892 per day. Mean hematopoietic stem cell transplantation cost was $352&#8239;333; mean 3-month terminal care cost was $107 013. …”
    Get full text
    Article
  6. 2846

    Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV s... by Muhit Özcan, Ryan D. Cassaday, Ewa Zarzycka, Erik Vandendries, Fan Zhang, Ying Chen, Alejandra Nieto, Fatih Demirkan, Pau Montesinos, Fevzi Altuntas

    Published 2025-01-01
    “…Previous studies reported higher rates of post– hematopoietic stem cell transplant (HSCT) hepatic sinusoidal obstruction syndrome (SOS) in patients receiving InO versus chemotherapy prior to HSCT. …”
    Get full text
    Article
  7. 2847
  8. 2848

    Variational Approaches for Drug-Disease-Gene Links in Periodontal Inflammation by Pradeep Kumar Yadalam, Prabhu Manickam Natarajan, Musab Hamed Saeed, Carlos M. Ardila

    Published 2025-02-01
    “…Introduction and Objectives: Oral diseases, including gingivitis and periodontitis, are linked to the Wnt signaling pathway, vital for bone metabolism, cementum homeostasis, and mesenchymal stem cell differentiation. Advances in generative AI techniques, such as variational autoencoders (VAEs) and quantum variational classifiers (QVCs), offer promising tools for predicting gene associations between drugs and diseases. …”
    Get full text
    Article
  9. 2849

    Lung transplantation for pulmonary chronic graft-versus-host disease: a missed opportunity? by Andrea Zajacova, MD, Hélène Schoemans, MD, PhD, Mark Greer, MD, MRCP, Hildegard Greinix, MD, Peter Jaksch, MD, Osnat Shtraichman, MD, Rayid Abdulqawi, MD, PhD, Are M. Holm, MD, PhD, Robin Vos, MD, PhD, Saskia Bos, MD, PhD

    Published 2025-02-01
    “…Chronic graft-versus-host disease is a common complication after allogeneic hematopoietic stem cell transplantation, with pulmonary chronic graft-versus-host disease (PcGvHD) particularly associated with a dismal prognosis. …”
    Get full text
    Article
  10. 2850

    Complex Variant of Philadelphia Translocation Involving Chromosomes 9, 12, and 22 in a Case with Chronic Myeloid Leukaemia by F. Malvestiti, C. Agrati, S. Chinetti, A. Di Meco, S. Cirrincione, M. Oggionni, B. Grimi, F. Maggi, G. Simoni, F. R. Grati

    Published 2014-01-01
    “…Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder included in the broader diagnostic category of myeloproliferative neoplasms, associated with fusion by BCR gene at chromosome 22q11 to ABL1 gene at chromosome 9q34 with the formation of the Philadelphia (Ph) chromosome. …”
    Get full text
    Article
  11. 2851
  12. 2852
  13. 2853

    EZH2 inhibition induces pyroptosis via RHA-mediated S100A9 overexpression in myelodysplastic syndromes by Qi Zhang, Yingwan Luo, Li Ye, Yuxia Wang, Lu Wang, Wenli Yang, Wei Lang, Shuanghong Zhu, Lingxu Jiang, Weimei Jin, Chen Mei, Xinping Zhou, Yanling Ren, Liya Ma, Gaixiang Xu, Bowatte Gedara Lakmal Vimukthi Bandara Bowattage, Hongyan Tong, Jie Sun

    Published 2025-01-01
    “…Abstract Myelodysplastic Syndromes (MDS) represent a group of heterogeneous myeloid clonal diseases derived from aberrant hematopoietic stem/progenitor cells. Enhancer of zeste homolog 2 (EZH2) is an important regulator in gene expression through methyltransferase-dependent or methyltransferase-independent mechanisms. …”
    Get full text
    Article
  14. 2854

    N-Cadherin promotes cardiac regeneration by potentiating pro-mitotic β-Catenin signaling in cardiomyocytes by Yi-Wei Tsai, Yi-Shuan Tseng, Yu-Shuo Wu, Wei-Lun Song, Min-Yi You, Yun-Chia Hsu, Wen-Pin Chen, Wei-Han Huang, Jia-Ci Chng, Chai-Ling Lim, Ke-Hsuan Wei, Shih-Lei Ben Lai, Wen-Chih Lee, Kai-Chien Yang

    Published 2025-01-01
    “…N-Cadherin knockdown reduces, whereas overexpression increases, the proliferation activity of neonatal mouse CMs and human induced pluripotent stem cell-derived CMs. Mechanistically, N-Cadherin binds and stabilizes pro-mitotic transcription regulator β-Catenin, driving CM self-renewal. …”
    Get full text
    Article
  15. 2855
  16. 2856

    Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study by Juan M. Cano-Calderón, Juan F. Zazueta-Pozos, Adán G. Gallardo-Rodríguez, Carlos Martínez-Murillo, Irma Olarte-Carrillo, Adolfo Martínez-Tovar, Christian O. Ramos-Peñafiel

    Published 2025-01-01
    “…Materials and methods: Retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the VTD or TD combination. …”
    Get full text
    Article
  17. 2857

    Utility of Endoscopic Examination in the Diagnosis of Acute Graft-versus-Host Disease in the Lower Gastrointestinal Tract by Kosuke Nomura, Toshiro Iizuka, Daisuke Kaji, Hisashi Yamamoto, Yasutaka Kuribayashi, Masami Tanaka, Tsukasa Furuhata, Satoshi Yamashita, Daisuke Kikuchi, Akira Matsui, Toshifumi Mitani, Yasunori Ota, Shuichi Taniguchi, Shu Hoteya

    Published 2017-01-01
    “…Of 1231 patients who underwent allogeneic hematopoietic stem cell transplantation between January 2005 and December 2014, 186 of whom underwent colonoscopy and biopsy and had no cytomegalovirus infection. …”
    Get full text
    Article
  18. 2858

    Osteoblastic Differentiation and Mitigation of the Inflammatory Response in Titanium Alloys Decorated with Oligopeptides by Aroa Álvarez-López, Raquel Tabraue-Rubio, Rafael Daza, Luis Colchero, Gustavo V. Guinea, Martine Cohen-Solal, José Pérez-Rigueiro, Daniel González-Nieto

    Published 2025-01-01
    “…We also find that RGD is the best-performing peptide in in vitro cell cultures, enhancing adhesion, proliferation, and osteogenic differentiation of mesenchymal stem cells. …”
    Get full text
    Article
  19. 2859

    Assessing Donor Site Morbidity and Impact on Quality of Life in Free Flap Microsurgery: An Overview by Florin-Vlad Hodea, Cristian-Sorin Hariga, Eliza-Maria Bordeanu-Diaconescu, Andrei Cretu, Catalina-Stefania Dumitru, Vladut-Alin Ratoiu, Ioan Lascar, Andreea Grosu-Bularda

    Published 2024-12-01
    “…Furthermore, the integration of regenerative medicine strategies, such as stem cell therapy and fat grafting, and technological innovations, including virtual reality rehabilitation and biofeedback devices, has shown promise in enhancing recovery and minimizing long-term complications. …”
    Get full text
    Article
  20. 2860

    CircTTC13 promotes sorafenib resistance in hepatocellular carcinoma through the inhibition of ferroptosis by targeting the miR-513a-5p/SLC7A11 axis by Ying Zhang, Ruiwei Yao, Mingyi Li, Chongkai Fang, Kunliang Feng, Xiuru Chen, Jinan Wang, Rui Luo, Hanqian Shi, Xinqiu Chen, Xilin Zhao, Hanlin Huang, Shuwei Liu, Bing Yin, Chong Zhong

    Published 2025-01-01
    “…Many first-line chemotherapeutic drugs induce ferroptosis, a form of programmed cell death dependent on ferrous iron-mediated oxidative stress, suggesting that drug resistance and ensuing tumor progression may in part stem from reduced ferroptosis. …”
    Get full text
    Article